Invo BioScience ROE 2010-2024 | NAYA
Current and historical return on equity (ROE) values for Invo BioScience (NAYA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Invo BioScience ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-06-30 |
$-0.01B |
$0.00B |
-1400.00% |
| 2024-03-31 |
$-0.01B |
$0.00B |
2800.00% |
| 2023-12-31 |
$-0.01B |
$0.00B |
3200.00% |
| 2023-09-30 |
$-0.01B |
$0.00B |
1200.00% |
| 2023-06-30 |
$-0.01B |
$-0.00B |
2200.00% |
| 2023-03-31 |
$-0.01B |
$0.00B |
-1600.00% |
| 2022-12-31 |
$-0.01B |
$-0.00B |
-533.33% |
| 2022-09-30 |
$-0.01B |
$0.00B |
-211.76% |
| 2022-06-30 |
$-0.01B |
$0.00B |
-177.78% |
| 2022-03-31 |
$-0.01B |
$0.01B |
-147.37% |
| 2021-12-31 |
$-0.01B |
$0.01B |
-126.32% |
| 2021-09-30 |
$-0.01B |
$0.00B |
-222.22% |
| 2021-06-30 |
$-0.01B |
$0.00B |
-333.33% |
| 2021-03-31 |
$-0.01B |
$0.01B |
-900.00% |
| 2020-12-31 |
$-0.01B |
$0.01B |
533.33% |
| 2020-09-30 |
$-0.01B |
$-0.00B |
125.00% |
| 2020-06-30 |
$-0.00B |
$-0.00B |
100.00% |
| 2020-03-31 |
$-0.00B |
$-0.00B |
80.00% |
| 2019-12-31 |
$-0.00B |
$-0.00B |
57.14% |
| 2019-09-30 |
$-0.00B |
$-0.00B |
61.54% |
| 2019-06-30 |
$-0.00B |
$-0.00B |
30.77% |
| 2019-03-31 |
$-0.00B |
$-0.00B |
85.71% |
| 2018-12-31 |
$-0.00B |
$-0.00B |
75.00% |
| 2018-09-30 |
$-0.00B |
$-0.00B |
44.44% |
| 2018-06-30 |
$-0.00B |
$-0.00B |
42.11% |
| 2018-03-31 |
$0.00B |
$-0.01B |
0.00% |
| 2017-12-31 |
$0.00B |
$-0.01B |
0.00% |
| 2017-09-30 |
$0.00B |
$-0.01B |
0.00% |
| 2017-06-30 |
$0.00B |
$-0.01B |
0.00% |
| 2017-03-31 |
$-0.00B |
$-0.01B |
22.22% |
| 2016-12-31 |
$-0.00B |
$-0.01B |
23.53% |
| 2016-09-30 |
$-0.00B |
$-0.00B |
25.00% |
| 2016-06-30 |
$-0.00B |
$-0.00B |
33.33% |
| 2016-03-31 |
$-0.00B |
$-0.00B |
200.00% |
| 2015-12-31 |
$-0.00B |
$-0.00B |
400.00% |
| 2015-09-30 |
$-0.00B |
|
533.33% |
| 2015-06-30 |
$-0.00B |
|
266.67% |
| 2015-03-31 |
$0.00B |
|
0.00% |
| 2011-12-31 |
$0.00B |
$-0.00B |
0.00% |
| 2011-09-30 |
$0.00B |
$-0.00B |
0.00% |
| 2011-06-30 |
$0.00B |
$-0.00B |
0.00% |
| 2011-03-31 |
$0.00B |
$-0.00B |
0.00% |
| 2010-12-31 |
$0.00B |
$-0.00B |
-50.00% |
| 2010-09-30 |
$0.00B |
$-0.00B |
-44.44% |
| 2010-06-30 |
$-0.00B |
$-0.00B |
66.67% |
| 2010-03-31 |
$-0.00B |
$-0.00B |
72.73% |
| 2009-12-31 |
$-0.00B |
$-0.00B |
160.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.004B |
$0.003B |
|
INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East.
|
